Premium
Distribution of Hepatitis A Antibody over a Process for the Preparation of a High‐Purity Factor VIII Concentrate
Author(s) -
Hart H.,
Jones A.,
McIntosh R.V.,
Cuthbertson B.,
Cubie H.
Publication year - 1994
Publication title -
vox sanguinis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.68
H-Index - 83
eISSN - 1423-0410
pISSN - 0042-9007
DOI - 10.1111/j.1423-0410.1994.tb00977.x
Subject(s) - antibody , potency , hepatitis , immunology , medicine , virology , chemistry , in vitro , biochemistry
The levels of hepatitis A antibody were studied in factor VIII products manufactured by the Scottish National Blood Transfusion Service. It was found that the current high‐purity factor VIII product has no detectable hepatitis A antibody, whereas the superseded intermediate‐purity product had significant antibody levels (6,700 mIU/ml). Although the finished high‐potency factor VIII product has no detectable hepatitis A antibody, significant levels of antibody are found in the early stages of product manufacture. This antibody may offer some protection against hepatitis A contamination present in very occasional plasma donations. Antibody to parvovirus B19 is also present at intermediate stages in the manufacture of high‐potency factor VIII, but its significance is not known. Hepatitis A antibody levels were also measured in normal immunoglobulin. These data indicate that antibody levels in the plasma pools used to manufacture factor VIII are falling.